title: Clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer.
abstract: The aim of this study was to evaluate the clinical outcome of CyberKnife stereotactic body radiotherapy (SBRT) for patients with stage I non-small cell lung cancer (NSCLC). Fifty patients with peripheral stage I NSCLC who refused surgery or were medically inoperable were treated with 48-60 Gy (median dose: 57 Gy) in three divided doses. Histopathology was available in 86% of patients. Thirty patients had a T1 tumor, and 20 patients had T2 tumors. More than 95% of the target volume was covered by the 72% isodose surface. Fiducials were implanted in or near the tumors in all patients to track tumor movement and breathing patterns. The median follow-up time was 35 months (3-45 months). Based on computed tomography scans, 40 patients achieved complete remission, six patients achieved partial remission, two patients exhibited stable disease, and two patients had progressive disease. The local control rate (CR + PR) was 92%, and the 2-year disease control rate (CR + PR + SD) was 96%. Overall survival for the whole group was 86% at 1 year and 74% at 2 years. Grade III toxicity occurred in two patients (4%) after marker placement. Treatment-related late grade III toxicity occurred in five patients (10%). Toxicities greater than grade III were not observed. CyberKnife SBRT achieves a high rate of local control and long-term curative effect with acceptable toxicity for patients with inoperable stage I NSCLC. However, long-term follow-up is necessary to evaluate survival and late toxicity.
authors: Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.
authors: Ze-Tian
authors: ZT
authors: Shen
authors: Xin-Hu
authors: XH
authors: Wu
authors: Bing
authors: B
authors: Li
authors: Xi-Xu
authors: XX
authors: Zhu
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
references: Comput Aided Surg. 2007 Sep;12(5):253-61
references: 17957532
references: Clin Lung Cancer. 2007 Sep;8(8):488-92
references: 17922973
references: Cancer Radiother. 2008 Dec;12(8):793-9
references: 18706844
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Radiother Oncol. 2009 Jun;91(3):296-300
references: 19297048
references: JAMA. 2010 Mar 17;303(11):1070-6
references: 20233825
references: Ann Thorac Surg. 2003 Apr;75(4):1097-101
references: 12683544
references: Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1015-24
references: 11072158
references: Lancet Oncol. 2012 Aug;13(8):802-9
references: 22727222
references: Chest. 2003 Nov;124(5):1946-55
references: 14605072
references: Neurosurgery. 2004 Jan;54(1):157-61; discussion 161-2
references: 14683553
references: J Thorac Cardiovasc Surg. 1988 Sep;96(3):440-7
references: 2842549
references: Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):517-23
references: 8226143
references: Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
references: 7677489
references: Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):149-54
references: 9422571
references: J Clin Oncol. 2006 Oct 20;24(30):4833-9
references: 17050868
references: Cancer J. 2007 Mar-Apr;13(2):87-94
references: 17476136
references: Int J Med Robot. 2005 Jan;1(2):28-39
references: 17518376
references: Med Phys. 2007 Jul;34(7):2774-84
references: 17821984
references: Radiat Oncol. 2007;2:39
references: 17953752